RSLS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 birž. 2024 @ 22:01):
Our systems believe the stock currently is overvalued by -0.14% compare to its pairs and should correct downwards.

Stats
Šios dienos apimtis	286 423
Vidutinė apimtis	5.78M
Rinkos kapitalizacija	4.54M
EPS	$-0.0935 ( Q1 \| 2024-05-15 )
Kita pelno data	( $-0.120 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.440 (Sector) 42.63 (Industry) 0
ATR14	$0 (0.00%)

AEMD -10.20%

AFIB 0.50%

AHCO 0.67%

AHPI 0.00%

ALGN 3.02%

ANIK -0.27%

APEN 0.00%

APYX 0.00%

ARAY 5.76%

ATEC 0.74%

AXDX 2.99%

AXGN 3.02%

AXNX -0.94%

AZYO 2.05%

BBLG -0.82%

BIOL 10.45%

BJDX -37.81%

BMRA 5.91%

BRKR 0.08%

BSGM 9.53%

BWAY -1.44%

CERS -0.59%

CFMS 0.44%

CLPT -2.33%

CODX 0.75%

CSII 0.15%

CTKB -1.48%

CTSO 1.65%

CUTR 0.36%

CVRX 6.52%

DCTH -3.25%

DXCM 3.02%

DYNT 0.41%

EAR -4.10%

ECOR 1.13%

EDAP -1.52%

ESTA -1.35%

FONR 2.56%

HJLI -1.98%

HSDT -1.92%

HSKA 0.00%

HYPR 7.64%

IART -0.92%

ICAD 0.78%

ICCM -2.34%

IINN 0.01%

INGN -0.77%

INMD -3.39%

IRIX 0.94%

IRMD -0.05%

IRTC 1.02%

ISO 0.00%

ITMR 0.00%

KIDS -0.38%

LHDX 0.00%

LIVN 0.46%

LNSR 1.69%

LUCD 3.67%

LUNG 1.41%

MASS -2.14%

MDGS 10.28%

MOTS 22.00%

MOVE 5.47%

MSON 0.00%

NAOV 0.41%

NARI 0.96%

NMRD 0.00%

NNOX -0.46%

NPCE 4.32%

NTUS 0.00%

NURO -1.07%

NUVA -2.24%

NUWE -34.53%

NVCN 0.00%

NVNO -4.02%

OBLN -5.86%

OFIX 0.85%

OM -7.01%

PACB -2.14%

PAVM 2.55%

PETV -16.20%

PODD 0.17%

PRCT -0.83%

PROF 3.87%

QIPT 2.79%

QTRX -2.21%

RCEL -1.39%

RPID -4.07%

RSLS -3.64%

RWLK 6.07%

RXST 0.80%

SGHT 3.20%

SIBN 3.66%

SIEN -18.69%

SILK -0.30%

SINT 1.89%

SOLY 0.00%

SRDX -0.02%

SRGA 0.00%

SRTS 1.74%

SWAV 0.00%

TBIO 2.71%

TCMD -0.62%

TELA -0.29%

THMO 4.17%

TIVC 0.77%

TLIS -4.72%

TMCI 5.50%

TMDI 0.00%

TMDX -0.78%

TNDM 0.40%

TNON 0.98%

UFPT -1.46%

VERO -2.44%

VIVE 0.00%

VMD 0.79%

VRAY 0.00%

VREX 0.21%

VVOS 2.30%

XAIR -1.37%

XENT 0.00%

ZIMV 1.52%

Insider Trading

Date	Person	Action	Amount	type
2024-01-05	Schneid Yair	Sell	0	Common Stock
2023-08-04	Stankovich Thomas	Sell	108	Common Stock, $0.001 par value per share
2023-08-24	Stankovich Thomas	Sell	39	Common Stock, $0.001 par value per share
2023-09-01	Stankovich Thomas	Sell	118	Common Stock, $0.001 par value per share
2023-10-11	Stankovich Thomas	Sell	39	Common Stock, $0.001 par value per share

INSIDER POWER
-2.16
Last 95 transactions
Buy: 10 386 223 \| Sell: 2 711 639

Koreliacija (AI algo v.1.1b): Overvalued: -0.14% $0.194 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.03 (neutral)

Trumpas: -0.19 (neutral)

Signal:(46.469) Neutral

ReShape Lifesciences Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
VRM	0.943
REVB	0.938
SGML	0.935
PRSO	0.932
IRBT	0.928
PLL	0.928
RDHL	0.923
HAFC	0.922
CNSP	0.921
AXDX	0.919

10 Labiausiai neigiamai susiję koreliacijos
FLXS	-0.924
LCUT	-0.92
HQY	-0.92
YMAB	-0.917
VCEL	-0.912
VERA	-0.9
INBK	-0.897
TARS	-0.896
FSEA	-0.896
MOR	-0.894

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

ReShape Lifesciences Inc Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

ReShape Lifesciences Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$8.68M
Bruto pelnas:	$5.55M (63.93 %)
EPS:	$-1.910

FY	2023
Pajamos:	$8.68M
Bruto pelnas:	$5.55M (63.93 %)
EPS:	$-1.910

FY	2022
Pajamos:	$11.24M
Bruto pelnas:	$6.80M (60.52 %)
EPS:	$-108.90

FY	2021
Pajamos:	$13.60M
Bruto pelnas:	$8.35M (61.38 %)
EPS:	$-250.16

Financial Reports:

No articles found.

ReShape Lifesciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ReShape Lifesciences Inc

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.